Setting

Asia Pacific Preventive Vaccines Market 2020-2026 by Vaccine Type, Disease, Administration, Patient, and Country: COVID-19 Impact and Growth Opportunity

Published: 28 Nov 2020 | Report Code: 10247775 | Pages: 119

Asia Pacific preventive vaccines market will grow by 12.89% annually with a total addressable market cap of $97.2 billion over 2020-2026 owing to the rising healthcare expenditure, advancing vaccine technology, and rising need for preventive vaccines especially new COVID-19 vaccines. Highlighted with 33 tables and 51 figures, this 119-page report “Asia Pacific Preventive Vaccines Market 2020-2026 by Vaccine Type, Disease, Administration, Patient, and Country: COVID-19 Impact and Growth Opportunity” is based on a holistic research of the entire Asia Pacific preventive vaccines market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2016-2019 and provides forecast from 2020 till 2026 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific preventive vaccines market in every aspect of the classification from perspectives of Vaccine Type, Disease, Administration, Patient, and Country. Based on Vaccine Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2016-2026 included in each section. • Live/Attenuated Vaccines • Inactivated Vaccines • Subunit Vaccines • Toxoid Vaccines • Conjugate Vaccines • Recombinant Vector Vaccines • Other Vaccines Based on Disease, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2016-2026 included in each section. • Vaccines for Pneumococcal Disease • Vaccines for Poliovirus • Vaccines for Hepatitis • Vaccines for Influenza • Vaccines for Measles, Mumps, and Rubella (MMR) • Vaccines for Varicella • Vaccines for Human Papilloma Virus • Vaccines for COVID-19 • Vaccines for Other Diseases Based on Administration, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2016-2026 included in each section. • Intramuscular Route • Subcutaneous Route • Oral Route • Intravenous Injection • Other Administration Routes Based on Patient, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2016-2026 included in each section. Pediatric Vaccines • Pneumococcal • Measles, Mumps, and Rubella (MMR) • Varicella • Hepatitis • Poliovirus • Haemophilus Influenzae B (HIB) • Other Diseases Adult Vaccines • Influenza • Cervical Cancer • Hepatitis • Zoster • Other Diseases Geographically, the following national/local markets are fully investigated: • Japan • China • South Korea • Australia • India • Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka) For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2016-2026. The breakdown of key national markets by Vaccine Type, Disease, and Route of Administration over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Specifically, potential risks associated with investing in Asia Pacific preventive vaccines market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions. Key Players (this may not be a complete list and extra companies can be added upon request): AstraZeneca plc Bavarian Nordic A/S China National Biotec Group Company Ltd. CSL Ltd. Daiichi Sankyo Co. Ltd Emergent BioSolutions Inc. GlaxoSmithKline PLC Johnson & Johnson Merck & Co. Novavax, Inc. Pfizer Inc. Sanofi SA Takeda Pharmaceutical Co. Ltd (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Table Of Contents

1 Introduction	7
1.1 Industry Definition and Research Scope	7
1.1.1 Industry Definition	7
1.1.2 Research Scope	8
1.2 Research Methodology	11
1.2.1 Overview of Market Research Methodology	11
1.2.2 Market Assumption	12
1.2.3 Secondary Data	12
1.2.4 Primary Data	12
1.2.5 Data Filtration and Model Design	14
1.2.6 Market Size/Share Estimation	15
1.2.7 Research Limitations	16
1.3 Executive Summary	17
2 Market Overview and Dynamics	20
2.1 Market Size and Forecast	20
2.1.1 Impact of COVID-19 on World Economy	22
2.1.2 Impact of COVID-19 on the Market	25
2.2 Major Growth Drivers	27
2.3 Market Restraints and Challenges	30
2.4 Emerging Opportunities and Market Trends	33
2.5 Porter’s Fiver Forces Analysis	37
3 Segmentation of Asia Pacific Market by Vaccine Type	41
3.1 Market Overview by Vaccine Type	41
3.2 Live/Attenuated Vaccines	43
3.3 Inactivated Vaccines	44
3.4 Subunit Vaccines	45
3.5 Toxoid Vaccines	46
3.6 Conjugate Vaccines	47
3.7 Recombinant Vector Vaccines	48
3.8 Other Vaccines	49
4 Segmentation of Asia Pacific Market by Disease	50
4.1 Market Overview by Disease	50
4.2 Vaccines for Pneumococcal Disease	52
4.3 Vaccines for Poliovirus	53
4.4 Vaccines for Hepatitis	54
4.5 Vaccines for Influenza	55
4.6 Vaccines for Measles, Mumps, and Rubella (MMR)	56
4.7 Vaccines for Varicella	57
4.8 Vaccines for Human Papilloma Virus	58
4.9 Vaccines for COVID-19	59
4.10 Vaccines for Other Diseases	60
5 Segmentation of Asia Pacific Market by Administration	61
5.1 Market Overview by Administration	61
5.2 Intramuscular Route	63
5.3 Subcutaneous Route	64
5.4 Oral Route	65
5.5 Intravenous Injection	66
5.6 Other Administration Routes	67
6 Segmentation of Asia Pacific Market by Patient	68
6.1 Market Overview by Patient	68
6.2 Pediatric Vaccines	70
6.3 Adult Vaccines	72
7 Asia-Pacific Market 2019-2026 by Country	74
7.1 Overview of Asia-Pacific Market	74
7.2 China	77
7.3 Japan	80
7.4 India	84
7.5 Australia	87
7.6 South Korea	90
7.7 Rest of APAC Region	93
8 Competitive Landscape	95
8.1 Overview of Key Vendors	95
8.2 New Product Launch, Partnership, Investment, and M&A	98
8.3 Company Profiles	99
AstraZeneca plc	99
Bavarian Nordic A/S	101
China National Biotec Group Company Ltd.	102
CSL Ltd.	103
Daiichi Sankyo Co. Ltd	104
Emergent BioSolutions Inc.	105
GlaxoSmithKline PLC	106
Johnson & Johnson	107
Merck & Co.	108
Novavax, Inc.	109
Pfizer Inc.	110
Sanofi SA	111
Takeda Pharmaceutical Co. Ltd	112
9 Investing in Asia Pacific Market: Risk Assessment and Management	113
9.1 Risk Evaluation of Asia Pacific Market	113
9.2 Critical Success Factors (CSFs)	116
Related Reports and Products	119
?
List Of Tables

Table 1.  Snapshot of Asia Pacific Preventive Vaccines Market in Balanced Perspective, 2019-2026	18
Table 2. Growth Rate of World Real GDP, 2017-2021	23
Table 3.  Main Product Trends and Market Opportunities in Asia Pacific Preventive Vaccines Market	33
Table 4. Asia Pacific Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn	41
Table 5. Asia Pacific Preventive Vaccines Market by Disease, 2016-2026, $ mn	50
Table 6. Asia Pacific Preventive Vaccines Market by Administration, 2016-2026, $ mn	61
Table 7. Asia Pacific Preventive Vaccines Market by Patient, 2016-2026, $ mn	68
Table 8. Asia Pacific Preventive Vaccines Market: Pediatric Vaccines by Disease, 2016-2026, $ mn	71
Table 9. Asia Pacific Preventive Vaccines Market: Adult Vaccines by Disease, 2016-2026, $ mn	73
Table 10. APAC Preventive Vaccines Market by Country, 2016-2026, $ mn	75
Table 11. China Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn	78
Table 12. China Preventive Vaccines Market by Disease, 2016-2026, $ mn	78
Table 13. China Preventive Vaccines Market by Administration, 2016-2026, $ mn	79
Table 14. Japan Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn	82
Table 15. Japan Preventive Vaccines Market by Disease, 2016-2026, $ mn	82
Table 16. Japan Preventive Vaccines Market by Administration, 2016-2026, $ mn	83
Table 17. India Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn	85
Table 18. India Preventive Vaccines Market by Disease, 2016-2026, $ mn	85
Table 19. India Preventive Vaccines Market by C Administration, 2016-2026, $ mn	86
Table 20. Australia Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn	88
Table 21. Australia Preventive Vaccines Market by Disease, 2016-2026, $ mn	88
Table 22. Australia Preventive Vaccines Market by Administration, 2016-2026, $ mn	89
Table 23. South Korea Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn	91
Table 24. South Korea Preventive Vaccines Market by Disease, 2016-2026, $ mn	91
Table 25. South Korea Preventive Vaccines Market by Administration, 2016-2026, $ mn	92
Table 26. Preventive Vaccines Market in Rest of APAC by Country, 2016-2026, $ mn	94
Table 27. AstraZeneca plc: Company Snapshot	99
Table 28. AstraZeneca plc: Business Segmentation	99
Table 29. AstraZeneca plc: Product Portfolio	100
Table 30. AstraZeneca plc: Revenue, 2016-2018, $ mn	100
Table 31. AstraZeneca plc: Recent Developments	100
Table 32.  Risk Evaluation for Investing in Asia Pacific Market, 2019-2026	114
Table 33. Critical Success Factors and Key Takeaways	117

List Of Figures

Figure 1. Research Method Flow Chart	11
Figure 2. Breakdown of Primary Research	13
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation	15
Figure 4. Asia Pacific Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2026	17
Figure 5. Asia Pacific Preventive Vaccines Market, 2019-2026, $ mn	20
Figure 6. Development Stages of Preventive Vaccines	21
Figure 7. Impact of COVID-19 on Business	25
Figure 8. Primary Drivers and Impact Factors of Asia Pacific Preventive Vaccines Market	27
Figure 9. Primary Restraints and Impact Factors of Asia Pacific Preventive Vaccines Market	30
Figure 10. Investment Opportunity Analysis	34
Figure 11. Porter’s Fiver Forces Analysis of Asia Pacific Preventive Vaccines Market	37
Figure 12. Breakdown of Asia Pacific Preventive Vaccines Market by Vaccine Type, 2019-2026, % of Revenue	42
Figure 13. Contribution to Asia Pacific 2020-2026 Cumulative Revenue by Vaccine Type, Value ($ mn) and Share (%)	42
Figure 14. Asia Pacific Preventive Vaccines Market: Live/Attenuated Vaccines, 2016-2026, $ mn	43
Figure 15. Asia Pacific Preventive Vaccines Market: Inactivated Vaccines, 2016-2026, $ mn	44
Figure 16. Asia Pacific Preventive Vaccines Market: Subunit Vaccines, 2016-2026, $ mn	45
Figure 17. Asia Pacific Preventive Vaccines Market: Toxoid Vaccines, 2016-2026, $ mn	46
Figure 18. Asia Pacific Preventive Vaccines Market: Conjugate Vaccines, 2016-2026, $ mn	47
Figure 19. Asia Pacific Preventive Vaccines Market: Recombinant Vector Vaccines, 2016-2026, $ mn	48
Figure 20. Asia Pacific Preventive Vaccines Market: Other Vaccines, 2016-2026, $ mn	49
Figure 21. Breakdown of Asia Pacific Preventive Vaccines Market by Disease, 2019-2026, % of Revenue	51
Figure 22. Contribution to Asia Pacific 2020-2026 Cumulative Revenue by Disease, Value ($ mn) and Share (%)	51
Figure 23. Asia Pacific Preventive Vaccines Market: Vaccines for Pneumococcal Disease, 2016-2026, $ mn	52
Figure 24. Asia Pacific Preventive Vaccines Market: Vaccines for Poliovirus, 2016-2026, $ mn	53
Figure 25. Asia Pacific Preventive Vaccines Market: Vaccines for Hepatitis, 2016-2026, $ mn	54
Figure 26. Asia Pacific Preventive Vaccines Market: Vaccines for Influenza, 2016-2026, $ mn	55
Figure 27. Asia Pacific Preventive Vaccines Market: Vaccines for Measles, Mumps, and Rubella (MMR), 2016-2026, $ mn	56
Figure 28. Asia Pacific Preventive Vaccines Market: Vaccines for Varicella, 2016-2026, $ mn	57
Figure 29. Asia Pacific Preventive Vaccines Market: Vaccines for Human Papilloma Virus, 2016-2026, $ mn	58
Figure 30. Asia Pacific Preventive Vaccines Market: Vaccines for COVID-19, 2016-2026, $ mn	59
Figure 31. Asia Pacific Preventive Vaccines Market: Vaccines for Other Diseases, 2016-2026, $ mn	60
Figure 32. Breakdown of Asia Pacific Preventive Vaccines Market by Administration, 2019-2026, % of Revenue	62
Figure 33. Contribution to Asia Pacific 2020-2026 Cumulative Revenue by Administration, Value ($ mn) and Share (%)	62
Figure 34. Asia Pacific Preventive Vaccines Market: Intramuscular Route, 2016-2026, $ mn	63
Figure 35. Asia Pacific Preventive Vaccines Market: Subcutaneous Route, 2016-2026, $ mn	64
Figure 36. Asia Pacific Preventive Vaccines Market: Oral Route, 2016-2026, $ mn	65
Figure 37. Asia Pacific Preventive Vaccines Market: Intravenous Injection, 2016-2026, $ mn	66
Figure 38. Asia Pacific Preventive Vaccines Market: Other Administration Routes, 2016-2026, $ mn	67
Figure 39. Breakdown of Asia Pacific Preventive Vaccines Market by Patient, 2019-2026, % of Revenue	68
Figure 40. Contribution to Asia Pacific 2020-2026 Cumulative Revenue by Patient, Value ($ mn) and Share (%)	69
Figure 41. Asia Pacific Preventive Vaccines Market: Pediatric Vaccines, 2016-2026, $ mn	70
Figure 42. Asia Pacific Preventive Vaccines Market: Adult Vaccines, 2016-2026, $ mn	72
Figure 43. Breakdown of APAC Preventive Vaccines Market by Country, 2019 and 2026, % of Revenue	75
Figure 44. Contribution to APAC 2020-2026 Cumulative Revenue by Country, Value ($ mn) and Share (%)	76
Figure 45.  Preventive Vaccines Market in China, 2016-2026, $ mn	77
Figure 46.  Preventive Vaccines Market in Japan, 2016-2026, $ mn	81
Figure 47.  Preventive Vaccines Market in India, 2016-2026, $ mn	84
Figure 48.  Preventive Vaccines Market in Australia, 2016-2026, $ mn	87
Figure 49.  Preventive Vaccines Market in South Korea, 2016-2026, $ mn	90
Figure 50.  Preventive Vaccines Market in Rest of APAC, 2016-2026, $ mn	93
Figure 51. Growth Stage of Asia Pacific Preventive Vaccines Industry over the Forecast Period	95

Key Players (this may not be a complete list and extra companies can be added upon request): 
AstraZeneca plc	
Bavarian Nordic A/S	
China National Biotec Group Company Ltd.	
CSL Ltd.	
Daiichi Sankyo Co. Ltd	
Emergent BioSolutions Inc.	
GlaxoSmithKline PLC	
Johnson & Johnson	
Merck & Co.	
Novavax, Inc.	
Pfizer Inc.	
Sanofi SA	
Takeda Pharmaceutical Co. Ltd